Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
111.1 USD | -2.96% | +0.49% | -20.23% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company's enterprise value to sales, at 3.94 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.23% | 17.69B | C+ | ||
+12.15% | 227B | B | ||
+14.90% | 197B | B- | ||
+18.22% | 141B | B- | ||
+29.15% | 110B | A- | ||
+0.53% | 64.15B | A- | ||
+16.92% | 53.72B | B+ | ||
+6.33% | 51.75B | B+ | ||
+10.93% | 45.2B | A | ||
+5.87% | 37.37B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ILMN Stock
- Ratings Illumina, Inc.